Skip to content Skip to footer
Subscribe Now
EVENTS

HLTH USA 2025 | Oct 19-22 | Las Vegas, NV 

EVERYONE has a heroic story to tell, their own legend to fulfill and HLTH is forging ahead into new realms of possibilities, gathering 12,000+ influential leaders, executives and visionaries who are passionately creating the next generation of healthcare. At HLTH you can foster meaningful connections, gain insights on cutting-edge trends, enhance your professional journey, or…
August 12, 2025

Read more

VIEWPOINTS

Jazz Pharmaceuticals at ASCO 2025: Robert Iannone in a Stimulating Conversation with PharmaShots

Shots:   Jazz Pharmaceuticals and partners presented seven abstracts from their oncology development program at ASCO 2025   Robert Iannone, CMO, EVP, Global Head of Research and Development, and Chief Medical Officer at Jazz Pharmaceuticals, in an engaging discussion with PharmaShots, shared four-year follow-up data from an ongoing P-II trial of Ziihera in combination with CT for…
August 11, 2025

Read more

VIEWPOINTS

Healthcare Marketing: Tom Donnelly from Supreme Group in a Stimulating Dialogue Exchange with PharmaShots 

Shots:  Supreme Group recently announced its 8th acquisition, adding Nimble Works and Vital Works to its portfolio, strengthening its presence in healthcare marketing and communications  The acquisition brings together Nimble Works’ insight-driven creative strengths and Vital Works’ performance-focused digital expertise to navigate complex healthcare domains and accelerate data-driven growth marketing  Tom Donnelly, CEO of Supreme…
August 6, 2025

Read more

EVENTS

Discovery & Development Summit Asia 2025

Discovery & Development Summit Asia 2025 is Global Engage’s inaugural platform that brings together the Drug Discovery & Development, Nucleic Acid Therapeutics and Precision Medicine congresses. This summit allows the exploration of the full spectrum of therapeutic innovation, from early-stage discovery to clinical translation and commercialization. Attendees will gain insights into assay development, screening technologies,…
August 5, 2025

Read more

VIEWPOINTS

Enhancing Accessibility to Medicine: Joshua Salsi from Biocon Biologics in Conversation with PharmaShots 

Shots:  Biocon Biologics’ Yesintek, biosimilar to Stelara, has secured broad market access through inclusion in the formularies of all major pharmacy benefit managers (PBMs)  Yesintek offers strong financial support and a smooth transition process, positioning it as a preferred option for patients needing ustekinumab therapy  Joshua Salsi, Head of North America Commercial at Biocon Biologics,…
August 4, 2025

Read more

VIEWPOINTS

Combating Hematologic Malignancies: Dr. Petri Bono from Faron Pharmaceuticals in Conversation with PharmaShots 

Shots:   Myelodysplastic Syndrome (MDS) is a rare and aggressive blood cancer in which the bone marrow fails to produce enough healthy blood cells  As resistance to traditional treatments continues to rise among MDS patients, Faron Pharmaceuticals' Bexmab emerges as a promising alternative  Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, highlights Bexmab’s unique mechanism…
July 30, 2025

Read more

VIEWPOINTS

Unlocking Approval: John Hayslip from Verastem Oncology in an Illuminating Conversation with PharmaShots 

Shots:  Did you know that more than 80 % of Low-grade Serous Ovarian Cancer (LGSOC) patients experience recurrence?  The US FDA recently approved Verastem Oncology’s Avmapki Fakzynja Co-Pack, as the first ever treatment of patients with KRAS-mutated recurrent LGSOC  In an illuminating dialogue exchange with PharmaShots, John Hayslip, CMO at Verastem Oncology, provides a detailed overview…
July 28, 2025

Read more

Zai Lab
VIEWPOINTS

Zai Lab at ASCO 2025: Rafael G. Amado in an Illuminating Dialogue Exchange with PharmaShots 

Shots:  Recently, Zai Lab presented data from a Phase Ia/Ib study evaluating ZL‑1310, a DLL3 ADC, in patients with extensive‑stage small cell lung cancer, both as a monotherapy and in combination with atezolizumab  ZL‑1310 leverages TMALIN technology, enabling clinicians to deliver more targeted doses of chemotherapy to cancer cells, distinguishing the compound from current standard‑of‑care…
July 23, 2025

Read more

VIEWPOINTS

Next-Gen T Cell Engagers for Solid Tumors: Shaun Murphy in a Riveting Dialogue Exchange with PharmaShots

Shots:   Unlike hematologic malignancies, where the elimination of most or all tumor cells results in immunosuppression, making headways in solid tumors requires a new holistic approach when using T Cell Engagers  Abpro’s ABP-102/CT-P72, co-developed by Celltrion leverages a tetravalent format; bivalent for both HER2 and CD3  PharmaShots welcomes Shaun Murphy, Vice President, Nonclinical Research and…
July 21, 2025

Read more

Load more